Merlin Efraim

Hematology
Multiprofile Hospital for Active Treatment Sveta Marina EAD

Presentation(s):

• OC 73.1 - Updated Main Study Period and Long-Term Extension (LTE) Results With Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Immune Thrombocytopenia (ITP)

  Wednesday, July 13, 2022
  10:15 AM – 10:30 AM